Aurobindo Pharma Shares Hit 9-Month Low On US Price Fixing Lawsuit
Business | Thomson Reuters | Friday December 16, 2016
The lawsuit, filed in the US District Court for the District of Connecticut by 20 US states, also named Heritage Pharmaceuticals Inc, a company owned by Emcure Pharma Ltd, as a "ring leader" of the price manipulation.
Dr Reddy's Sees More Challenges In US Business
Business | Thomson Reuters | Thursday May 12, 2016
India's second largest drugmaker Dr Reddy's Laboratories Ltd is bracing for another challenging year in its biggest market, the United States, where its business has been hurt by regulatory scrutiny and fewer new drug approvals.
Dr Reddy's Blames Venezuelan Crisis For 86% Profit Drop
Business | Thomson Reuters | Thursday May 12, 2016
India's second-largest drugmaker, Dr Reddy's Laboratories Ltd , reported a much lower-than-expected quarterly profit due to a write-off related to Venezuela's economic crisis which has damaged its business there.
Dr Reddy's, TR-Pharm Announce Collaboration For 3 Biosimilars
Business | Pres Trust of India | Friday March 11, 2016
Pharma major Dr Reddy's Laboratories Ltd has entered into a strategic collaboration agreement with Turkey-based TR-Pharm involving three biosimilar products.
US Regulator Gives Dr Reddy's Additional Time to Respond to Warning Letter
Business | Press Trust of India | Thursday November 26, 2015
Dr Reddy's Laboratories Ltd (DRL) on Thursday said the US Food and Drug Administration (FDA) has extended the time for replying to the warning letter issued to the company by about two weeks to December 7.
US Court Imposes Temporary Sales Ban on Dr Reddy's Generic Heartburn Drug
Business | Thomson Reuters | Tuesday November 10, 2015
Dr Reddy's Laboratories Ltd, India's second largest drug maker by sales, said on Tuesday it had been temporarily barred by a US court from selling its generic form of blockbuster heartburn drug Nexium in the United States.
Dr Reddy's Plans Bigger Push on Biosimilars in Emerging Markets
Business | Thomson Reuters | Friday October 30, 2015
Dr Reddy's Laboratories Ltd plans to step up sales of biosimilars, or copies of complex biotech drugs, in emerging markets in the next few years, its chief operating officer said on Thursday.
AstraZeneca, Dr Reddy's Ink Diabetes Drug Distribution Pact
Business | Friday May 29, 2015
AstraZeneca Pharma India and Dr Reddy's Laboratories on Friday entered into a distribution agreement for two drugs - Riax and Riax-M - used for treatment of diabetes in India.
Dr Reddy's Files 3 New Drug Applications With FDA
Business | Tuesday April 7, 2015
Drug major Dr Reddy's Laboratories Ltd on Tuesday said it has filed three new drug applications (NDAs) aimed to be used in the treatments of psoriasis, rosacea, migraine, with the US Food and Drug Administration (FDA).
Dr Reddy's to Buy Select Brands From UCB for $128 Million
Business | Thomson Reuters | Wednesday April 1, 2015
The deal will help Dr Reddy's strengthen its presence in dermatology, pediatrics and respiratory products, the company said in a statement to the Bombay Stock Exchange.
Dr Reddy's Q4 Profit Up 25 Per Cent at Rs 471 Crore, Lags Estimates
Business | Tuesday May 13, 2014
Dr Reddy's Laboratories Ltd, India's second-largest drugmaker by sales, on Tuesday posted a 25 per cent rise in quarterly net profit, but fell short of analysts' estimates due to a rise in expenses.
Aurobindo Pharma Shares Hit 9-Month Low On US Price Fixing Lawsuit
Business | Thomson Reuters | Friday December 16, 2016
The lawsuit, filed in the US District Court for the District of Connecticut by 20 US states, also named Heritage Pharmaceuticals Inc, a company owned by Emcure Pharma Ltd, as a "ring leader" of the price manipulation.
Dr Reddy's Sees More Challenges In US Business
Business | Thomson Reuters | Thursday May 12, 2016
India's second largest drugmaker Dr Reddy's Laboratories Ltd is bracing for another challenging year in its biggest market, the United States, where its business has been hurt by regulatory scrutiny and fewer new drug approvals.
Dr Reddy's Blames Venezuelan Crisis For 86% Profit Drop
Business | Thomson Reuters | Thursday May 12, 2016
India's second-largest drugmaker, Dr Reddy's Laboratories Ltd , reported a much lower-than-expected quarterly profit due to a write-off related to Venezuela's economic crisis which has damaged its business there.
Dr Reddy's, TR-Pharm Announce Collaboration For 3 Biosimilars
Business | Pres Trust of India | Friday March 11, 2016
Pharma major Dr Reddy's Laboratories Ltd has entered into a strategic collaboration agreement with Turkey-based TR-Pharm involving three biosimilar products.
US Regulator Gives Dr Reddy's Additional Time to Respond to Warning Letter
Business | Press Trust of India | Thursday November 26, 2015
Dr Reddy's Laboratories Ltd (DRL) on Thursday said the US Food and Drug Administration (FDA) has extended the time for replying to the warning letter issued to the company by about two weeks to December 7.
US Court Imposes Temporary Sales Ban on Dr Reddy's Generic Heartburn Drug
Business | Thomson Reuters | Tuesday November 10, 2015
Dr Reddy's Laboratories Ltd, India's second largest drug maker by sales, said on Tuesday it had been temporarily barred by a US court from selling its generic form of blockbuster heartburn drug Nexium in the United States.
Dr Reddy's Plans Bigger Push on Biosimilars in Emerging Markets
Business | Thomson Reuters | Friday October 30, 2015
Dr Reddy's Laboratories Ltd plans to step up sales of biosimilars, or copies of complex biotech drugs, in emerging markets in the next few years, its chief operating officer said on Thursday.
AstraZeneca, Dr Reddy's Ink Diabetes Drug Distribution Pact
Business | Friday May 29, 2015
AstraZeneca Pharma India and Dr Reddy's Laboratories on Friday entered into a distribution agreement for two drugs - Riax and Riax-M - used for treatment of diabetes in India.
Dr Reddy's Files 3 New Drug Applications With FDA
Business | Tuesday April 7, 2015
Drug major Dr Reddy's Laboratories Ltd on Tuesday said it has filed three new drug applications (NDAs) aimed to be used in the treatments of psoriasis, rosacea, migraine, with the US Food and Drug Administration (FDA).
Dr Reddy's to Buy Select Brands From UCB for $128 Million
Business | Thomson Reuters | Wednesday April 1, 2015
The deal will help Dr Reddy's strengthen its presence in dermatology, pediatrics and respiratory products, the company said in a statement to the Bombay Stock Exchange.
Dr Reddy's Q4 Profit Up 25 Per Cent at Rs 471 Crore, Lags Estimates
Business | Tuesday May 13, 2014
Dr Reddy's Laboratories Ltd, India's second-largest drugmaker by sales, on Tuesday posted a 25 per cent rise in quarterly net profit, but fell short of analysts' estimates due to a rise in expenses.
................................ Advertisement ................................
................................ Advertisement ................................
